Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

163.73 +0.65 (+0.40%)
Official Closing Price Updated: 7:00 PM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
This Dividend Stock Has a $13 Billion Secret Weapon
Johnson & Johnson made a key decision last year. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma
Via Benzinga
Check Out What Whales Are Doing With JNJ
Via Benzinga
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
With Johnson & Johnson buying out Ambrx Biopharma, the win-win deal boosted AMAM stock while better positioning J&J’s oncology unit. 
Via InvestorPlace
J&J's Tentative $700M Agreement To Resolve Talc Powder-Related Lawsuits Across US States
Healthcare giant Johnson & Johnson (NYSE: JNJ) has reached a tentative agreement to pay approximately $700 million to settle an investigation  
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi 
Via Benzinga
Merck, the Dow's hottest stock, gets set to report Q4 financials
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks. 
Via MarketBeat
Topics Stocks
Exposures US Equities
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
The year's biggest medical conference kicked off with a melee of buyout news. 
Via Investor's Business Daily
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
From Johnson & Johnson
Via Business Wire
24 Top Dividend Stocks to Buy and Hold in 2024
These stocks could deliver positive gains in the new year -- but the real money-making opportunities are over the next decade and beyond. 
Via The Motley Fool
5 Top Investing Resolutions for 2024
You don't need a fortune to start investing today. 
Via The Motley Fool
Dow Darlings: Top 3 Stocks That Will Lead the Charge in 2024
These Dow stocks will perform better than others this year and take the leaderboard for strong gains and security. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
Exposures Product Safety
Illumina's MRD Technology For Cancer Testing Collaborates With Johnson & Johnson Unit
Illumina, Inc. (NASDAQ: ILMN) announced it has signed an agreement with Janssen Research & Development, a unit of Johnson & Johnson (NYSE: JNJ). 
Via Benzinga
Still Worried About a 2024 Recession? 7 Stocks to Watch.
Although many investors feel relief from avoiding a downcycle last year, those worried about a 2024 recession should see this list. 
Via InvestorPlace
Topics Economy
Exposures Economy
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
Revenge of the Boring Stocks! Dividends Are Sexy Again.
Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now. 
Via InvestorPlace
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely... 
Via Benzinga
Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth
U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC. 
Via Benzinga
Topics ETFs
3 No-Brainer Stocks to Buy With $1,000 Right Now for the New Year
A modest amount of money can go a long way when it's put to work in industry-leading, time-tested businesses with well-defined catalysts. 
Via The Motley Fool
Johnson & Johnson Shareholders' Class Action Lawsuit Gets Nod from Federal Judge
A federal judge's ruling in Trenton, New Jersey, has paved the way for Johnson & Johnson (NYSE: JNJ) shareholders to collectively proceed with a lawsuit alleging the company concealed information about... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Dogs Of The Dow: Top 10 Highest Yielding Dow Jones Stocks, How To Get Dividends Of 3% to 7.4% In 2024
Twenty eight of the 30 Dow Jones Industrial Average components pay out dividends. A look at the top ten highest dividend yields. 
Via Benzinga
Topics Stocks
Exposures US Equities
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In 2023
A look back at the best performing and worst performing Dow Jones Industrial Average stocks in 2023. 
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Is A Trending Stock: Facts To Know Before Betting On It
Johnson & Johnson (JNJ​​​​​​​) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's... 
Via Talk Markets
2024’s Blue-Chip Winners: Top 3 Stocks for Rock-Solid Returns
Some blue-chip stocks are poised to outperform others this year, so consider adding these to your portfolio. 
Via InvestorPlace
Meet the 2024 Dogs of the Dow
2023 was another tough year for this popular investing strategy, but fans are hoping for better results in the coming year. 
Via The Motley Fool
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.